Advances in Clinical and Experimental Medicine
2016, vol. 25, nr 2, March-April, p. 237–242
Publication type: original article
The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats
1 Department of Pharmacology, Eskisehir Osmangazi University School of Medicine, Eskişehir, Turkey
Background. Permeability glycoprotein (P-glycoprotein or P-gp) plays an important role in the intestinal absorption of the immunosuppressive agents: cyclosporine and tacrolimus.
Objectives. The aim of this study was to determine how the intestinal absorption of cyclosporine and tacrolimus is affected when they are used with P-gp activating or inhibiting agents.
Material and Methods. In in vitro experiments, everted parts of rat small intestines were used to evaluate the effects of verapamil (a P-gp inhibitor) and rifampicin (a P-gp inducer) on the intestinal absorption of cyclosporine and tacrolimus. In in vivo experiments, the effects of verapamil and rifampicin on the plasma concentrations of cyclosporine and tacrolimus were evaluated.
Results. In in vitro experiments, the absorption of cyclosporine and tacrolimus from the small intestine increased in a time-dependent manner when the drugs were administered with or without verapamil or rifampicin. There was no difference in the absorption of cyclosporine ± verapamil/rifampicin between the jejunum and ileum; however, ileal absorption of tacrolimus + rifampicin was significantly higher than jejunal absorption (p < 0.05). Plasma concentrations of cyclosporine and tacrolimus were significantly increased when they were co-administered with verapamil (p < 0.001) and significantly decreased when co-administered with rifampicin (p < 0.05).
Conclusion. P-gp may play an important role in the absorption of immunosupressive drugs, and it may contribute to drug-drug interactions thay may lead to inadequate drug response or toxicity.
P-glycoprotein, cyclosporine, tacrolimus, everted sac
- Hamman JH, Demana PH, Olivier EI: Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights 2007, 2, 71–81.
- Mouly S, Paine MF: P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003, 20, 1595–1599.
- Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M: Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 1999, 289, 149–155.
- Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Lennernas H: Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007, 4, 252–257.
- Nakayama A, Saitoh H, Oda M, Takada M, Aungst BJ: Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 2000, 11, 317–324.
- Kilic FS, Batu O, Sirmagul B, Yildirim E, Erol K: Intestinal absorption of digoxin and interaction with nimodipine in rats. Pol J Pharmacol 2004, 56, 137–141.
- Leu BL, Huang JD: Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother Pharmacol 1995, 35, 432–436.
- Takano M, Yumoto R, Murakami T: Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006, 109, 137–161.
- Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992, 267, 24248–24252.
- Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997, Suppl 40, 13–19.
- Finch CK, Chrisman CR, Baciewicz AM, Self TH: Rifampin and rifabutin drug interactions: An update. Arch Intern Med 2002, 162, 985–992.
- Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet 2003, 42, 819–850.
- Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Hebert MF: Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997, 62, 41–49.
- Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro–in vivo correlation. Br J Pharmacol 1996, 118, 1841–1847.
- Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268, 6077–6080.
- Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M: Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig 2014, 34, 651–659.
- Wind S, Giessmann T, Jungnik A, Brand T, Marzin K, Bertulis J, Hocke J, Gansser D, Stopfer P: Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014, 34, 173–182.
- Fudin J, Fontenelle DV, Payne A: Rifampin reduces oral morphine absorption: A case of transdermal buprenorphine selection based on morphine pharmacokinetics. J Pain Palliat Care Pharmacother 2012, 26, 362–367.
- Wilson TH, Wiseman G: The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. J Physiol 1954, 123, 116–125.
- Barthe L, Woodley J, Houin G: Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 1999, 13, 154–168.
- Stephens RH, O’Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G: Kinetic profiling of P-glycoproteinmediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001, 296, 584–591.
- Hashimoto Y, Sasa H, Shimomura M, Inui K: Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998, 15, 1609–1613.
- Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S: Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002, 91, 719–729.
- Saitoh H, Saikachi Y, Kobayashi M, Yamaguchi M, Oda M, Yuhki Y, Aungst BJ: Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci 2006, 28, 34–42.
- Chiou WL, Chung SM, Wu TC: Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm Res 2000, 17, 205–208.
- Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997, 27, 201–214.
- Flepisi BT, Bouic P, Sissolak G, Rosenkranz B: Drug-drug interactions in HIV positive cancer patients. Biomed Pharmacother 2014, Apr 28. pii: S0753-3322(14)00058-4. DOI: 10.1016/j.biopha.2014.04.010
- Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer 2006, 6, 546–558.
- Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT: Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol 2014, 77, 1039–1050.